- ￥2920 - 23600
- TargetMol
- 美国
- T10616
- 2025年07月09日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
零下80~20°C
- 保质期：
Powder: -20°C for 3 years In solvent: -80°C for 2 years
- 英文名：
BRM/BRG1 ATP Inhibitor-1
- 库存：
10
- 供应商：
TargetMol
- CAS号：
2270879-17-7
- 规格：
5 mg/50 mg/100 mg/1 mL/25 mg/1 mg/10 mg
| 规格： | 5 mg | 产品价格： | ￥6590.0 |
|---|---|---|---|
| 规格： | 50 mg | 产品价格： | ￥17500.0 |
| 规格： | 100 mg | 产品价格： | ￥23600.0 |
| 规格： | 1 mL | 产品价格： | ￥4720.0 |
| 规格： | 25 mg | 产品价格： | ￥12900.0 |
| 规格： | 1 mg | 产品价格： | ￥2920.0 |
| 规格： | 10 mg | 产品价格： | ￥8730.0 |
Product Introduction
Bioactivity
英文名:BRM/BRG1 ATP Inhibitor-1
描述:BRM/BRG1 ATP Inhibitor-1 is an allosteric dual Brahma homolog (BRM)/SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2) and BRG1/SMARCA4 ATPase activity inhibitor (IC50s<0.005 μM).
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验1. The recently discovered WYE-125132 and related drugs represent a new generation of ATP competitive and highly specific inhibitors targeting mTOR globally. As mTORC1 and mTORC2 mediate diverse sets of both redundant and distinctive cellular pathways of growth
Development of ATP-Competitive mTOR Inhibitors
mTOR inhibitor rapamycin and structurally related rapalogs have failed to show significant single-agent antitumor efficacy in most types of cancer. This limited clinical success may be due to the inability of the rapalogs to maintain a complete blockade
Chemoproteomic Characterization of Protein Kinase Inhibitors Using Immobilized ATP
kinase inhibitors are ATP-competitive inhibitors targeting the catalytic site of specific protein kinases, the large number of protein kinases that are encoded within eukaryotic genomes and the existence of many other cellular proteins that bind ATP
技术资料暂无技术资料 索取技术资料
